ClinicalTrials.gg
CompletedNCT03322800Updated Jun 9, 2021

A Study of AK0529 to Evaluate Pharmacokinetics and Safety in Chinese Healthy Volunteers

A Phase 1 interventional study of AK0529 and Placebo in Healthy, sponsored by Shanghai Ark Biopharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-09.

Sponsored by Shanghai Ark Biopharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study will characterize the pharmacokinetics (PK) of AK0529, the effect of food and evaluate the safety of AK0529 in healthy Chinese adult subjects. 50 subjects will be randomized to receive a dose level of AK0529 or placebo in five groups. The total study duration will be approximately 18-27 days for each subject.

Read the detailed description

This is a randomized, double-blind, placebo-controlled, single-center, Phase I study in healthy Chinese subjects. The objectives of the study are to evaluate the safety of AK0529, characterize the PK of AK0529 and to evaluate the effect of food in healthy Chinese subjects. 50 healthy Chinese subjects will be randomized to orally receive one of four dose levels of AK0529 (single dose:100 mg and 300 mg, Multiple dose: 600 mg, Cross-over Food Effect: 300 mg) or placebo. The total duration of the study will be approximately 18 to 27 days for each subject.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Shanghai Ark Biopharmaceutical Co., Ltd. is the lead sponsor of 20 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants between 18 and 45 years of age, inclusive.
  • Have a body weight ≥45 kg (Female) or ≥50 kg (Male), and a (BMI) between 19 and 26 kg/m\^2, inclusive.
  • Participants are in good health without any significant clinical abnormalities as determined by the investigator on the basis of medical history, physical examination (including vital signs) and baseline test results (hematology, blood chemistry, blood coagulation, urinalysis and 12-lead (ECG)).
  • Participants and the spouses who are willing to use a medically accepted method of (e.g. placement of an intrauterine device or intrauterine system, contraceptive drugs, using condom) during the study period and for one month thereafter.
  • Participants who are willing to sign and date the approved form (ICF).

Exclusion criteria

Exclusion Criteria:

  • Female subjects of have positive serum pregnancy test results or are lactating at screening.
  • Subjects who have their daily cigarette smoking to five or more for 3 months prior to screening.
  • History of severe or multiple drug allergies.
  • History of alcohol abuse in the past 3 months prior to screening (Alcohol consumption >14 units per week: 1 unit = 10 mL alcohol, 250mL of 4 degrees beer, 25 mL of 40 degrees spirit or 75 mL of 13 degrees wine).
  • History of any drug abuse, or have a positive urine drug screen result at screening, or history of any psychotropic medication abuse within 5 years prior to screening.
  • Previous exposure to any other Medicinal Product (IMP) or participation in any clinical trial within 3 months prior to screening.
  • Donation or loss of blood over 450 mL within 3 months prior to screening.
  • Use of any prescription, over-the-counter, herbs, or medications which can change the pH values of gastrointestinal tracts (e.g. antacids, H2 receptor inhibitors and/or proton-pump inhibitors) within 28 days prior to screening.
  • Receiving caffeine-containing food or drinks, or alcohol-containing products within 24 hours prior to study drug administration.
  • Smoking and use of any nicotine-containing products within 24 hours prior to study drug administration.
  • Have swallowing problems, or any gastrointestinal diseases or history of surgery (e.g. subtotal gastrectomy) that could possibly affect drug absorption.
  • abnormalities in the results.
  • Clinically significant abnormalities in the lab test results of biochemistry, hematology, blood coagulation or urinalysis above the (ULN) ranges as judged by the investigator.
  • Positive surface antigen (HBsAg), virus antibody (HCV Ab), (HIV-1 or HIV-2 antibody) or syphilis results.
  • Evidence of clinical significant digestive, urological, neurological,hematological, endocrine, oncological, pulmonary, immunological, cardiovascular, or psychiatric disease at screening.
  • ECG results with the , corrected for heart rate by Bazett's formula (QTcB) of > 450 msec in the supine position at screening.
  • Systolic blood pressure (SBP) > 140 mmHg or \< 90 mmHg, and/or diastolic blood pressure (DBP) > 90 mmHg or \< 60 mmHg in the seated position at screening.
  • Subjects are lactose intolerant.
  • Inability to meet the study requirements in the opinion of the investigator.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    AK0529 100 mg, Pilot

    This is an open pilot arm and male subjects enrolled into this arm will be only administered with an oral single dose of 100 mg AK0529. The dose group begins treatment on Day 1.

    Drug: AK0529

  • Experimental
    AK0529 100 mg

    Subjects will be administered with an oral single dose of 100 mg AK0529 or placebo. The dose group begins treatment on Day 1.

    Drug: AK0529 · Other: Placebo

  • Experimental
    AK0529 300 mg, food effect

    A 3x3 cross-over study is designed in this group to evaluate the food effect following a standard Chinese meal or a high fat meal in the same subjects, comparing with the PK profile of AK0529 under fasted condition. Subjects will be administered with an oral dose of 300 mg AK0529 or placebo on Day 1 of each cycle.

    Drug: AK0529 · Other: Placebo

  • Experimental
    AK0529 600 mg

    Subjects will be administered with an oral single dose of 600 mg AK0529 or placebo. The dose group begins treatment on Day 1.

    Drug: AK0529 · Other: Placebo

  • Experimental
    AK0529 300 mg, MAD

    Subjects will be administered with the multiple doses of 300 mg AK0529 or placebo on Day 1-7.

    Drug: AK0529 · Other: Placebo

  • Other
    Placebo

    For assessment of the Adverse Event (AE) profile, there are placebo controls in each dose group (except the pilot group). The placebo is administered at the same time (and of the same dosage) as the AK0529 subjects.

    Other: Placebo

Interventions

  • DrugAK0529

    Active Substance: AK0529, Pharmaceutical Form: Capsule, Route of Administration: Oral

  • OtherPlacebo

    Active Substance: Placebo, Pharmaceutical Form: Capsule, Route of Administration: Oral

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    The maximum observed plasma concentration of AK0529.

    Time frame: Day1 (pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12 hrs post-dose), Day2 (24 hrs post-dose), Day3 (48 hrs post-dose), Day4 (72 hrs post-dose), Day5, Day6, Day7, Day8, Day9 and Day10

  2. Time to Maximum Plasma Concentration (Tmax)

    The time of occurrence of Cmax.

    Time frame: Day1 (pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12 hrs post-dose), Day2 (24 hrs post-dose), Day3 (48 hrs post-dose), Day4 (72 hrs post-dose), Day5, Day6, Day7, Day8, Day9 and Day10

  3. Area under the plasma concentration-time curve from time zero up to time (AUC 0-t)

    The area under the plasma concentration-time curve from time zero up to the last analytically quantifiable concentration of AK0529.

    Time frame: Day1 (pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12 hrs post-dose), Day2 (24 hrs post-dose), Day3 (48 hrs post-dose), Day4 (72 hrs post-dose), Day5, Day6, Day7, Day8, Day9 and Day10

  4. Terminal Half-Life (t1/2)

    The apparent elimination half-life of AK0529.

    Time frame: Day1 (pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12 hrs post-dose), Day2 (24 hrs post-dose), Day3 (48 hrs post-dose), Day4 (72 hrs post-dose), Day5, Day6, Day7, Day8, Day9 and Day10

  5. Area Under the Plasma Concentration-Time Curve Extrapolated to Infinity (AUC0-inf)

    The area under the plasma concentration-time curve from time zero up extrapolated to infinity of AK0529.

    Time frame: Day1 (pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12 hrs post-dose), Day2 (24 hrs post-dose), Day3 (48 hrs post-dose), Day4 (72 hrs post-dose), Day5, Day6, Day7, Day8, Day9 and Day10

  6. Apparent Oral Clearance (CL/F)

    The oral clearance of AK0529

    Time frame: Day1 (pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12 hrs post-dose), Day2 (24 hrs post-dose), Day3 (48 hrs post-dose), Day4 (72 hrs post-dose), Day5, Day6, Day7, Day8, Day9 and Day10

  7. Percentage of Subjects with Adverse Events (AEs)

    An adverse event can be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.

    Time frame: From baseline up to approximately 6 weeks

07

Study locations

1 site
  • Shanghai Xuhui Central Hospital
    Shanghai, 201203, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Apr 2018, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2017
First posted
Oct 26, 2017
StartActual
Oct 23, 2017
Primary completionActual
Apr 6, 2018
CompletionActual
May 24, 2018
Last update
Jun 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03322800
Lead sponsor
Shanghai Ark Biopharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Oct 26, 2017
Start date
Oct 23, 2017
Primary completion
Apr 6, 2018
Completion
May 24, 2018
Last update
Jun 9, 2021

Study contacts

Jimmy Gu
study director · info@arkbiosciences.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ziresovir

Start the discussion